BPG is committed to discovery and dissemination of knowledge
Review
Copyright ©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 114040
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.114040
Tight junction proteins: Gatekeepers turned facilitators in the pathogenesis of gastric adenocarcinoma
Shobha Selvam, Balasubramaniyan Vairappan
Shobha Selvam, Balasubramaniyan Vairappan, Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India
Co-first authors: Shobha Selvam and Balasubramaniyan Vairappan.
Author contributions: Selvam S and Vairappan B contributed equally to this manuscript and are co-first authors. Selvam S and Vairappan B contributed to the manuscript writing and revisions.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Balasubramaniyan Vairappan, PhD, Additional Professor, Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanvantari Nagar, Pondicherry 605006, India. balasubramaniyan.v@jipmer.edu.in
Received: September 10, 2025
Revised: October 21, 2025
Accepted: November 24, 2025
Published online: January 15, 2026
Processing time: 124 Days and 10.1 Hours
Core Tip

Core Tip: Tight junction (TJ) proteins play a pivotal role in preserving the integrity of the gastric epithelial barrier. Their dysregulation represents a critical early event linking chronic inflammation to gastric carcinogenesis. Inflammatory mediators induce TJ remodeling, thereby increasing mucosal permeability and promoting tumor initiation and progression. Emerging therapeutic strategies targeting TJ proteins either by pharmacologically restoring barrier integrity or modulating aberrant TJ signaling offer promising avenues to suppress inflammation, inhibit tumor growth and metastasis, and ultimately improve clinical outcomes in gastric cancer patients.